Ultragenyx vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Ultragenyx (RARE)

Q3 20265 Aug – 3 Sep 2026

▲3▼1

Ultragenyx wins gene-therapy approval but Angelman trial fails

Q2 revenue jump and narrower loss Ultragenyx's second-quarter loss narrowed to 90 cents a share and revenue rose 28% to a record $214 million, beating expectations. The company kept its full-year revenue guidance. This supports the stock by showing the commercial business is growing and funding pipeline work.
It shows the underlying business is healthy, which matters for valuation even after the trial failure.
FDA approves Genglycos gene therapy The FDA granted accelerated approval to Genglycos (DTX401) for glycogen storage disease type Ia, the first gene therapy for this rare disorder. It has a $2.7 million list price and should launch within 30-60 days. This adds a new commercial product, though the patient pool is tiny (1,500-2,500 in the U.S.).
A new approved product is a major positive driver for future revenue.
96-week data reinforces Genglycos benefit Published 96-week data showed Genglycos cut daily cornstarch intake by 61% and helped many patients eliminate nighttime doses, with a tolerable safety profile. This strengthens the case for the newly approved therapy and supports doctor and payer confidence.
It backs up the approval with longer-term evidence, helping adoption.
Angelman syndrome trial fails, stock plunges The Phase 3 Aspire study of apazunersen (GTX-102) missed its primary and key secondary goals, wiping 43-46% off the stock to an all-time low. Analysts downgraded the stock, citing a complete miss. The company will cut expenses and review the program, but the commercial business offers some valuation floor.
This is the biggest new negative event, directly causing the stock's collapse.

August 20265 Aug – 3 Sep 2026

▲3▼1

Ultragenyx wins gene-therapy approval but Angelman trial fails

Q2 revenue jump and narrower loss Ultragenyx's second-quarter loss narrowed to 90 cents a share and revenue rose 28% to a record $214 million, beating expectations. The company kept its full-year revenue guidance. This supports the stock by showing the commercial business is growing and funding pipeline work.
It shows the underlying business is healthy, which matters for valuation even after the trial failure.
FDA approves Genglycos gene therapy The FDA granted accelerated approval to Genglycos (DTX401) for glycogen storage disease type Ia, the first gene therapy for this rare disorder. It has a $2.7 million list price and should launch within 30-60 days. This adds a new commercial product, though the patient pool is tiny (1,500-2,500 in the U.S.).
A new approved product is a major positive driver for future revenue.
96-week data reinforces Genglycos benefit Published 96-week data showed Genglycos cut daily cornstarch intake by 61% and helped many patients eliminate nighttime doses, with a tolerable safety profile. This strengthens the case for the newly approved therapy and supports doctor and payer confidence.
It backs up the approval with longer-term evidence, helping adoption.
Angelman syndrome trial fails, stock plunges The Phase 3 Aspire study of apazunersen (GTX-102) missed its primary and key secondary goals, wiping 43-46% off the stock to an all-time low. Analysts downgraded the stock, citing a complete miss. The company will cut expenses and review the program, but the commercial business offers some valuation floor.
This is the biggest new negative event, directly causing the stock's collapse.

Latest5 Aug – 3 Sep 2026

▲3▼1

Ultragenyx wins gene-therapy approval but Angelman trial fails

Q2 revenue jump and narrower loss Ultragenyx's second-quarter loss narrowed to 90 cents a share and revenue rose 28% to a record $214 million, beating expectations. The company kept its full-year revenue guidance. This supports the stock by showing the commercial business is growing and funding pipeline work.
It shows the underlying business is healthy, which matters for valuation even after the trial failure.
FDA approves Genglycos gene therapy The FDA granted accelerated approval to Genglycos (DTX401) for glycogen storage disease type Ia, the first gene therapy for this rare disorder. It has a $2.7 million list price and should launch within 30-60 days. This adds a new commercial product, though the patient pool is tiny (1,500-2,500 in the U.S.).
A new approved product is a major positive driver for future revenue.
96-week data reinforces Genglycos benefit Published 96-week data showed Genglycos cut daily cornstarch intake by 61% and helped many patients eliminate nighttime doses, with a tolerable safety profile. This strengthens the case for the newly approved therapy and supports doctor and payer confidence.
It backs up the approval with longer-term evidence, helping adoption.
Angelman syndrome trial fails, stock plunges The Phase 3 Aspire study of apazunersen (GTX-102) missed its primary and key secondary goals, wiping 43-46% off the stock to an all-time low. Analysts downgraded the stock, citing a complete miss. The company will cut expenses and review the program, but the commercial business offers some valuation floor.
This is the biggest new negative event, directly causing the stock's collapse.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.